The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study
Open accessAbstract
OBJECTIVE: To assess the efficacy of rituximab (RTX) in SSc. METHODS: Fourteen patients with SSc were evaluated. Eight patients were randomized to receive two cycles of RTX at baseline and 24 weeks [each cycle consisted of four weekly RTX infusions (375 mg/m(2))] in addition to standard treatment, whereas six patients (control group) received standard treatment alone. Lung involvement was assessed by pulmonary function tests (PFTs) and chest high-resolution CT (HRCT). Skin involvement was assessed both clinically and histologically. RESULTS: There was a significant increase of forced vital capacity (FVC) in the RTX group compared with baseline (mean +/- s.d.: 68.13 +/- 19.69 vs 75.63 +/- 19.73, at baseline vs 1-year, respectively, P = 0.0018). The median percentage of improvement of FVC in the RTX group was 10.25%, whereas that of deterioration in the controls was 5.04% (P = 0.002). Similarly, diffusing capacity of carbon monoxide (DL(CO)) increased significantly in the RTX group compared with baseline (mean +/- s.d.: 52.25 +/- 20.71 vs 62 +/- 23.21, at baseline vs 1-year respectively, P = 0.017). The median percentage of improvement of DL(CO) in the RTX group was 19.46%, whereas that of deterioration in the control group was 7.5% (P = 0.023). Skin thickening, assessed with the Modified Rodnan Skin Score (MRSS), improved significantly in the RTX group compared with the baseline score (mean +/- s.d.: 13.5 +/- 6.84 vs 8.37 +/- 6.45 at baseline vs 1-year, respectively, P < 0.001). CONCLUSION: Our results indicate that RTX may improve lung function in patients with SSc. To confirm our encouraging results we propose that larger scale, multicentre studies with longer evaluation periods are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoyles, R. K., Ellis, R. W., Wellsbury, J., Lees, B., Newlands, P., Goh, N. S. L., Roberts, C., Desai, S., Herrick, A. L., McHugh, N. J., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22204 · Cited by 732
Cited by
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Jordan, S., Distler, J. H. W., Maurer, B., Huscher, D., van Laar, J. M., Allanore, Y., Distler, O., Airo, P., Sancho, J. J. A., Ananjeva, L., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204522 · Cited by 434
Systemic sclerosis-associated interstitial lung disease
Perelas, A., Silver, R. M., Arrossi, A. V., & Highland, K. B. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30480-1 · Cited by 422
The Pathogenesis of Systemic Sclerosis
Katsumoto, T. R., Whitfield, M. L., & Connolly, M. K. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130312 · Cited by 313
Solomon, J. J., Olson, A. L., Fischer, A., Bull, T., Brown, K. K., & Raghu, G. (2013) · European Respiratory Review · doi:10.1183/09059180.00005512 · Cited by 294
Metadata
- Authors
- Daoussis, D., Liossis, S.-N. C., Tsamandas, A. C., Kalogeropoulou, C., Kazantzi, A., Sirinian, C., Karampetsou, M., Yiannopoulos, G., & Andonopoulos, A. P.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-11-18
- Volume
- 49
- Issue
- 2
- Pages
- 271-280
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2165992621
- Cited by
- 394
- References
- 1
- FWCI
- 14.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. https://app.cochat.ai/papers/10.1093/rheumatology/kep093
- The paper
- Daoussis, D., Liossis, S.-N. C., Tsamandas, A. C., Kalogeropoulou, C., Kazantzi, A., Sirinian, C., Karampetsou, M., Yiannopoulos, G., & Andonopoulos, A. P. (2010). Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology. https://doi.org/10.1093/rheumatology/kep093
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.